Compared with nonusers, adults taking GLP-1s had a: 17 percent lower risk of venous thromboembolism, or blood clots in the veins 31 percent lower risk of pulmonary embolism, a potentially life-threatening clot that travels to the lungs 21 percent lower risk of going to the emergency department 44 percent lower risk of all-cause mortality (death from any cause) Researchers also observed lower stroke rates among GLP-1 users, although this difference didnt reach statistical significance
In addition to its effects on appetite, semaglutide lowers blood sugar by increasing insulin production after a meal
After FDA approval, Eli Lilly needs several months to scale manufacturing and distribute through pharmacies
As doses change and side effects emerge, that approach fragments data, obscures context, and wastes clinicians' time
So what they're really asking is something to increase longevity, not to reverse aging processes